Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.

ABSTRACT:

Background

Outcomes in children and adolescents with recurrent or progressive high-grade glioma are poor, with a historical median overall survival of 5.6 months. Pediatric high-grade gliomas are largely immunologically silent or "cold," with few tumor-infiltrating lymphocytes. Preclinically, pediatric brain tumors are highly sensitive to oncolytic virotherapy with genetically engineered herpes simplex virus type 1 (HSV-1) G207, which lacks genes essential for replication in normal brain tissue.

Methods

We conducted a phase 1 trial of G207, which used a 3+3 design with four dose cohorts of children and adolescents with biopsy-confirmed recurrent or progressive supratentorial brain tumors. Patients underwent stereotactic placement of up to four intratumoral catheters. The fol

SUBMITTER: Friedman GK 

PROVIDER: S-EPMC8284840 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature